US lawmakers are pushing for more scrutiny of Chinese investment in pharmaceuticals and biotechnology, as Washington’s strategic competition with Beijing expands beyond semiconductors and artificial intelligence into the healthcare sector. Bipartisan US senators on Wednesday unveiled legislation aimed at increasing transparency around foreign influence in the pharmaceutical industry, amid growing concerns over US dependence on China for critical drug ingredients and medical supply chains. “There...